NEW YORK, Jan. 2 — Panacea Pharmaceuticals has added former US Food & Drug Administration commissioner Frank Young to its board of directors, the company said Wednesday. Young, with expertise in genetics, biotechnology, regulatory issues and defense applications of bioscience, will help guide the company's efforts to use functional genomics in developing new therapeutics and diagnostics for cancer and central nervous system diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.